XENEXenon Pharmaceuticals Inc
XENE
Xenon Pharmaceuticals Inc2,742
Mkt Cap
$5.26BVolume
84.0052W High
$63.9552W Low
$28.19PE Ratio
-11.56XENE Fundamentals
Price
$54.39Prev Close
$56.00Open
$55.6450D MA
$56.36Beta
0.86Avg. Volume
913,855.41EPS (Annual)
-$4.36P/B
3.93Rev/Employee
$20,270.27$3,011.21
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus
XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.
Zacks·10d ago
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been given a consensus recommendation of "Buy" by the eighteen analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a bu...
MarketBeat·12d ago
Xenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on Monday
Xenon Pharmaceuticals (NASDAQ:XENE) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...
MarketBeat·14d ago
Jennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE
Jennison Associates LLC boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.8% during the fourth quarter, according to the company in its most recent...
MarketBeat·17d ago
Pictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENE
Pictet Asset Management Holding SA decreased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 50.4% in the fourth quarter, according to its most recent Form 13F...
MarketBeat·17d ago
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the typical daily volume of 165 put options...
MarketBeat·18d ago
Xenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton Conference
Xenon Pharmaceuticals (NASDAQ:XENE) provided an update on its clinical and pipeline progress at the Bloom Burton conference, with CEO Ian Mortimer highlighting recent Phase III results for lead program azetukalner, plans for regulatory filings, and continued expansion into psychiatry and pain.
Lead...
MarketBeat·22d ago
Peregrine Capital Management LLC Invests $7.84 Million in Xenon Pharmaceuticals Inc. $XENE
Peregrine Capital Management LLC acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to the company in its most recent...
MarketBeat·24d ago
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by Brokerages
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has received a consensus recommendation of "Buy" from the nineteen analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a buy rating...
MarketBeat·1mo ago
<
1
2
...
>